Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: The TEMPO trial

Annals of the Rheumatic Diseases

Volumn 65, Issue 3, 2006, Pages 328-334

  Van Der Heijde, D ^a   Klareskog, L ^b   Singh, A ^c   Tornero, J ^d   Melo Gomes, J ^e   Codreanu, C ^f   Pedersen, R ^c   Freundlich, B ^c   Fatenejad, S ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c PFIZER INC   (United States)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e SERVIMED   (Portugal)

^f Centrul de Boli Reumatismale   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; NONOXINOL 9; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 33144458951     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.035709     Document Type: Article

References (27)

1. ACR. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update, Arthritis Rheum 2002;46:328-46.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
3. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
4. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Klareskog L, van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
6. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-3.
7. Kvien TK, Heiberg T. Patient perspective in outcome assessments- perceptions or something more? J Rheumatol 2003;30:873-6.
8. Scott DL. Pursuit of optimal outcomes in rheumatoid arthritis. Pharmacoeconomics 2004;22(suppl 1):13-26.
9. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22(suppl 1):27-38.
10. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
11. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
12. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eiqht-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med 1998;17:679-96.
15. Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999;26:712-16.
16. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther 2003;25:993-1001.
17. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley, 1999.
18. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
19. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
20. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35.
21. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953-60.
22. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York, UK: Centre for Health Economics, University of York, 1999, report No 172..
23. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004;7:204-15.
24. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
25. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
26. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-39.
27. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.